- Home
- FBYD vs AUTL Comparison
FBYD vs AUTL Comparison
Compare FBYD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- AUTL
- Stock Information
- Founded
- FBYD 2021
- AUTL 2014
- Country
- FBYD United States
- AUTL United Kingdom
- Employees
- FBYD N/A
- AUTL N/A
- Industry
- FBYD
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBYD
- AUTL Health Care
- Exchange
- FBYD Nasdaq
- AUTL Nasdaq
- Market Cap
- FBYD 300.5M
- AUTL 359.3M
- IPO Year
- FBYD N/A
- AUTL 2018
- Fundamental
- Price
- FBYD $6.54
- AUTL $2.07
- Analyst Decision
- FBYD
- AUTL Strong Buy
- Analyst Count
- FBYD 0
- AUTL 5
- Target Price
- FBYD N/A
- AUTL $9.32
- AVG Volume (30 Days)
- FBYD 14.7K
- AUTL 2.5M
- Earning Date
- FBYD 05-15-2025
- AUTL 05-08-2025
- Dividend Yield
- FBYD N/A
- AUTL N/A
- EPS Growth
- FBYD N/A
- AUTL N/A
- EPS
- FBYD N/A
- AUTL N/A
- Revenue
- FBYD $6,937,000.00
- AUTL $9,011,000.00
- Revenue This Year
- FBYD N/A
- AUTL $329.53
- Revenue Next Year
- FBYD N/A
- AUTL $191.73
- P/E Ratio
- FBYD $426.53
- AUTL N/A
- Revenue Growth
- FBYD N/A
- AUTL N/A
- 52 Week Low
- FBYD $3.62
- AUTL $1.11
- 52 Week High
- FBYD $13.25
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- FBYD 42.91
- AUTL 76.19
- Support Level
- FBYD $5.94
- AUTL $1.19
- Resistance Level
- FBYD $7.00
- AUTL $1.79
- Average True Range (ATR)
- FBYD 0.51
- AUTL 0.12
- MACD
- FBYD -0.02
- AUTL 0.07
- Stochastic Oscillator
- FBYD 36.36
- AUTL 90.70
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.